Specialty biopharmaceutical firm AbbVie, Inc. (NYSE: ABBV) Thursday introduced second-quarter 2024 monetary outcomes, reporting a decline in adjusted earnings and a rise in revenues. The numbers exceeded estimates.
The corporate reported worldwide web revenues of $14.46 billion for the June quarter, up 4.3% from the corresponding interval of 2023 and above the market’s projection. All working segments, besides the Eye Care division, registered development.
Web revenue, adjusted for particular objects, declined to $2.65 per share in Q2 from $2.91 per share within the year-ago quarter, however topped expectations. On a reported foundation, second-quarter revenue was $1.37 billion or $0.77 per share, in comparison with $2.02 billion or $1.14 per share final 12 months.